{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T07:10:31Z","timestamp":1742541031493,"version":"3.40.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2021YFC2500300"],"award-info":[{"award-number":["2021YFC2500300"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370183"],"award-info":[{"award-number":["82370183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-2-007"],"award-info":[{"award-number":["2023-I2M-2-007"]}]},{"name":"Tian Jin Natural Science Foundation","award":["23JCZXJC00310"],"award-info":[{"award-number":["23JCZXJC00310"]}]},{"name":"Haihe Laboratory of Cell Ecosystem Innovation Fund","award":["HH22KYZX0039"],"award-info":[{"award-number":["HH22KYZX0039"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"crossref","award":["Y-SYBLD2022ZD-0031"],"award-info":[{"award-number":["Y-SYBLD2022ZD-0031"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Acute myeloid leukemia (AML) is a highly heterogeneous myeloid malignancy which can be classified by genetic aberrations. To evaluate the impact of the dynamin 2 mutation in AML, we systematically assessed the characteristics and prognostic of <jats:italic>DNM2<\/jats:italic> mutated patients in AML. In 912 AML patients, 20 somatic mutations in the <jats:italic>DNM2<\/jats:italic> gene were identified among the 18 <jats:italic>DNM2<\/jats:italic> mutated AML patients (2%). Of the mutation events, 60% (12\/20) were in the dynamin central region of <jats:italic>DNM2<\/jats:italic>. <jats:italic>DNM2<\/jats:italic>mutations were preferentially occurred in AML with <jats:italic>CEBPA<\/jats:italic> mutation (11\/18, 61.1%), or <jats:italic>RUNX1::RUNX1T1<\/jats:italic> fusion gene (6\/18, 33.3%). <jats:italic>DNM2<\/jats:italic> mutations were associated with better overall survival (<jats:italic>P<\/jats:italic>\u2009=\u20090.028), event-free survival (<jats:italic>P<\/jats:italic>\u2009=\u20090.0093) and trends towards better relapse-free survival (<jats:italic>P<\/jats:italic>\u2009=\u20090.08), which seems potentially attribute to its coexisting with <jats:italic>CEBPA<\/jats:italic> mutation and <jats:italic>RUNX1::RUNX1T1<\/jats:italic> fusion gene. Our study demonstrated the clinical characteristics and the role of <jats:italic>DNM2<\/jats:italic> mutations in AML, which might facilitate understanding the pathogenesis of AML.<\/jats:p>","DOI":"10.1186\/s40164-025-00628-5","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T06:50:25Z","timestamp":1742539825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamin2 mutations in newly diagnosed acute myeloid leukemia: clinical characteristics, and prognostic significance"],"prefix":"10.1186","volume":"14","author":[{"given":"Kunpeng","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaowei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"628_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40164-020-00161-7","volume":"9","author":"J Yu","year":"2020","unstructured":"Yu J, Li Y, Zhang D, Wan D, Jiang Z. Clinical implications of recurrent gene mutations in acute myeloid leukemia. Exp Hematol Oncol. 2020;9:4.","journal-title":"Exp Hematol Oncol"},{"key":"628_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2162-3619-3-13","volume":"3","author":"B Leeke","year":"2014","unstructured":"Leeke B, Marsman J, O\u2019Sullivan JM, Horsfield JA. Cohesin mutations in myeloid malignancies: underlying mechanisms. Exp Hematol Oncol. 2014;3:13.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"628_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40164-021-00207-4","volume":"10","author":"W Guan","year":"2021","unstructured":"Guan W, Zhou L, Li Y, et al. Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns. Exp Hematol Oncol. 2021;10(1):27.","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"628_CR4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40(8):850-864.e9.","journal-title":"Cancer Cell"},{"issue":"23","key":"628_CR5","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"628_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","volume":"13","author":"L Huang","year":"2020","unstructured":"Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u20132020). J Hematol Oncol. 2020;13(1):143.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"628_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","volume":"12","author":"S Qin","year":"2019","unstructured":"Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019;12(1):27.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"628_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-022-01336-x","volume":"15","author":"EA Medina","year":"2022","unstructured":"Medina EA, Delma CR, Yang FC. ASXL1\/2 mutations and myeloid malignancies. J Hematol Oncol. 2022;15(1):127.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"628_CR9","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1091\/mbc.8.12.2553","volume":"8","author":"DE Warnock","year":"1997","unstructured":"Warnock DE, Baba T, Schmid SL. Ubiquitously expressed dynamin-II has a higher intrinsic GTPase activity and a greater propensity for self-assembly than neuronal dynamin-I. Mol Biol Cell. 1997;8(12):2553\u201362.","journal-title":"Mol Biol Cell"},{"issue":"1","key":"628_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1091\/mbc.01-07-0380","volume":"13","author":"EM van Dam","year":"2002","unstructured":"van Dam EM, Stoorvogel W. Dynamin-dependent transferrin receptor recycling by endosome-derived clathrin-coated vesicles. Mol Biol Cell. 2002;13(1):169\u201382.","journal-title":"Mol Biol Cell"},{"issue":"1","key":"628_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13046-021-02045-y","volume":"40","author":"D Trochet","year":"2021","unstructured":"Trochet D, Bitoun M. A review of dynamin 2 involvement in cancers highlights a promising therapeutic target. J Exp Clin Cancer Res. 2021;40(1):238.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00628-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00628-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00628-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T06:50:32Z","timestamp":1742539832000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00628-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["628"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00628-5","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional ethics committee of Blood Diseases Hospital Ethics Committee have approved the research. Ethic number is IIT2020024-EC-1. The overall design and conduction of the research was fully accordance with the Declaration of Helsinki. Written informed consent was collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed to submit the manuscript. Everyone has no discrepancy for the research content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}